Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath® technique

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 430-438

  Fransson, Per ^a   Bergström, Per ^a   Löfroth, Per Olov ^a   Widmark, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Complications; Dose escalation; Prostate cancer; Radiotherapy; Self assessment

Indexed keywords

DISEASE CONTROL; DRUG DOSAGE; RADIOTHERAPY; TOXICITY; TUMORS;

BEAMCATH® TECHNIQUE; DOSE ESCALATION; PROSTATE CANCER; SELF-ASSESSMENT;

PATIENT TREATMENT;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE CANCER SYMPTOM SCALE; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; SCORING SYSTEM; SYMPTOM; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; INTESTINES; MALE; MIDDLE AGED; MUCUS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; URINARY BLADDER; URINARY CATHETERIZATION; URINARY INCONTINENCE;

EID: 33748328166     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.007     Document Type: Article

References (37)

1. Leibel S.A., Hanks G.E., and Kramer S. Patterns of care outcome studies: Results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 10 (1984) 401-409
2. Hanks G.E., Martz K.L., and Diamond J.J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15 (1988) 1299-1305
3. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
4. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
5. Dearnaley D.P., Hall E., Lawrence D., Huddart R.A., Eeles R., Nutting C.M., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
6. Chism D.B., Horwitz E.M., Hanlon A.L., Pinover W.H., Mitra R.K., and Hanks G.E. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 55 (2003) 71-77
7. Hanks G.E., Hanlon A.L., Epstein B., and Horwitz E.M. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
8. Michalski J.M., Purdy J.A., Winter K., Roach M., Vijayakumar S., Sandler H.M., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46 (2000) 391-402
9. Hanks G.E., Hanlon A.L., Schultheiss T.E., Pinover W.H., Movsas B., Epstein B.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
10. Teshima T., Hanks G.E., Hanlon A.L., Peter R.S., and Schultheiss T.E. Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 39 (1997) 77-83
11. Zelefsky M.J., Cowen D., Fuks Z., Shike M., Burman C., Jackson A., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85 (1999) 2460-2468
12. Nguyen L.N., Pollack A., and Zagars G.K. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire. Urology 51 (1998) 991-997
13. Dearnaley D.P., Khoo V.S., Norman A.R., Meyer L., Nahum A., Tait D., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353 (1999) 267-272
14. Brundage M., Lukka H., Crook J., Warde P., Bauman G., Catton C., et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer-A systematic review. Radiother Oncol 64 (2002) 239-250
15. Zelefsky M.J., Fuks Z., and Leibel S.A. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 12 (2002) 229-237
16. Teh B.S., Mai W.Y., Grant W.H., Chiu J.K., Lu H.H., Carpenter L.S., et al. Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control. Cancer Invest 20 (2002) 437-451
17. Bergström P., Löfroth P.-O., and Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer-A new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 42 (1998) 305-311
18. de Boer H.C., van Os M.J., Jansen P.P., and Heijmen B.J. Application of the No Action Level (NAL) protocol to correct for prostate motion based on electronic portal imaging of implanted markers. Int J Radiat Oncol Biol Phys 61 (2005) 969-983
19. Fransson P., Löfroth P.-O., Franzén L., Henriksson R., Bergström P., and Widmark A. Acute side effects after dose-escalation treatment of prostate cancer using the new urethral catheter BeamCath technique. Acta Oncol 40 (2001) 756-765
20. Fransson P., Bergström P., Löfroth P.-O., Franzén L., Henriksson R., and Widmark A. Daily-diary evaluated side effects of dose-escalation radiotherapy of prostate cancer using the stereotactic BeamCath technique. Acta Oncol 42 (2003) 326-333
21. Fransson P., Bergström P., Lofroth P.-O., and Widmark A. Prospective evaluation of urinary and intestinal side effects after BeamCath stereotactic dose-escalated radiotherapy of prostate cancer. Radiother Oncol 63 (2002) 239-248
22. Widmark A., Fransson P., and Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 74 (1994) 2520-2532
23. Fransson P., and Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Cancer 78 (1996) 1066-1078
24. Fransson P., and Widmark A. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 85 (1999) 678-688
25. Fransson P., Tavelin B., and Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer 9 (2001) 187-198
26. Landberg T., Chavaudra J., Dobbs J., Hanks G.E., Johansson K.-A., Möller T., et al. ICRU REPORT 50. Prescribing, recording and reporting photon beam therapy (1993), International Commission on Radiation Units and Measurements, Bethesda
27. Fransson P. Quality of life and side effects in patients with localized prostate cancer. Evaluation with self-assessment questionnaires (2000), Umeå University, Umeå, Sweden
28. Soffen E.M., Hanks G.E., Hunt M.A., and Epstein B.E. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 24 (1992) 485-488
29. Roach M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
30. Zelefsky M.J., Leibel S.A., Gaudin P.B., Kutcher G.J., Fleshner N.E., Venkatramen E.S., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
31. Little D.J., Kuban D.A., Levy L.B., Zagars G.K., and Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 62 (2003) 707-713
32. Pollack A., Hanlon A., Horwitz E.M., Feigenberg S., Uzzo R.G., and Price R.A. Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 21 (2003) 200-208
33. O'Brien P.C., Hamilton C.S., Denham J.W., Gourlay R., and Franklin C.I. Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 75-80
34. Symon Z., Griffith K.A., McLaughlin P.W., Sullivan M., and Sandler H.M. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57 (2003) 384-390
35. Litwin M.S., and McGuigan K.A. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 17 (1999) 2882-2888
36. Goldner G., Wachter-Gerstner N., Wachter S., Dieckmann K., Janda M., and Pötter R. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. Differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 179 (2003) 320-327
37. Pickett B., Kurhanewicz J., Pouliot J., Weinberg V., Shinohara K., Coakley F., et al. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65 (2006) 65-72